New funding awards - April 2020

Friday, May 15, 2020

Sponsored Research

Adam Devore of Cardiology has received a sub-award (5K23-HL142835-03) through the Dartmouth College for a project entitled "The Impact of Quality Metrics on Outcomes among Elderly Heart Failure Patients." Total funding will be $35,034.

Adrian Hernandez of Cardiology has received an award from the Patient-Centered Outcomes Research Institute for a project entitled "HERO Program, HERO Registry, HERO-HCQ Trial." Total funding will be $40,819,060.

Han Kim of Cardiology has received a sub-award (5U01-HL117006-05) through the MedStar Health Research Institute for a project entitled "HCMR.2 Hypertrophic Cardiomyopathy Registry." Total funding will be $1.

Christopher Kontos of Cardiology has received a sub-award (7R01-HL141325-02) through the Augusta University for a project entitled "The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery Disease." Total funding will be $145,225.

Matthew Roe of Cardiology has received an award from the Patient-Centered Outcomes Research Institute for a project entitled "ADAPTABLE Supplement." Total funding will be $445,466.

Jatin Roper of Gastroenterology has received an award (PC190582-W81XWH-20-1-0203) from the Department of Defense for a project entitled "Treatment of radiation proctitis in prostate cancer patients with a novel inducer of autophagy." Total funding will be $1,207,500.

Leigh Boulware of General Internal Medicine has received a sub-award (7R01-DK111952-04) through the University of Virginia - Charlottesville for a project entitled "Integrated Mineral Metabolism Treatment Strategies in Patients on Dialysis." Total funding will be $149,931.

Cathleen Colon-Emeric of Geriatrics has received an award (3UH3-AG056925-03S1) from the National Institutes of Health for a project entitled "Physical Resiliencies: Indicators and Mechanisms in the Elderly Collaborative Administrative Supplement." Total funding will be $868,012.

Mitchell Horwitz of Hematologic Malignancies and Cellular Therapy has received a sub-award (5U24-HL138660-) through the National Marrow Donor Program for a project entitled "Study Agreement #816977 Related to BMT CTN 1703/1801 Study." Total funding will be $1.

Yubin Kang of Hematologic Malignancies and Cellular Therapy has received an award (1R21-CA234701-01) from the National Institutes of Health for a project entitled "Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma." Total funding will be $384,541.

Lindsay Rein of Hematologic Malignancies and Cellular Therapy has received an award from the American Society of Hematology for a project entitled "Targeting Beta-arrestins in myeloid malignancies." Total funding will be $50,000.

Deverick Anderson of Infectious Diseases has received an award from the Patient-Centered Outcomes Research Institute for a project entitled "PCORI healthcare worker prophylaxis study Drug for COVID-19 Patients." Total funding will be $0.

Gregory Gray of Infectious Diseases has received a sub-award (5K01-OH011432-02-00) through the Boston University for a project entitled "Epidemiologic and genomic evaluation of influenza D among cattle workers and their community." Total funding will be $9,771.

Joshua Thaden of Infectious Diseases has received a sub-award () through the University Medical Center Utrecht for a project entitled "Prospective epidemiological study to estimate the O-serotype distribution of extraintestinal pathogenic Escherichia coli (ExPEC) isolated from hospitalized patients aged 60 years or older with invasive ExPEC disease (IED) and to evaluate the clinical." Total funding will be $1.

Patty Lee of Pulmonary has received an award (-W81XWH1610680 P00001-PR15080) from the Department of Defense for a project entitled "MIF-Based Therapies in Cigarette Smoke-Related COPD and Pneumonia." Total funding will be $471,769.

Kamran Mahmood of Pulmonary has received an award (W81XWH2010280 LC190500) from the Department of Defense for a project entitled "Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions." Total funding will be $161,000.

Industry-sponsored Clinical Trials

Geoffrey Ginsburg of Cardiology has received a sub-award (NNJ15HK11B) through KBRwyle for a project entitled "One-Carbon Metabolism Genetics Data Analyses." Total funding will be $131,876.

Han Kim of Cardiology has received an award from Guerbet for a project entitled "T1 Mapping vs Contrast Enhanced CMR for the Detection of Chronic MI." Total funding will be $199,662.

David Leiman of Gastroenterology has received an award from Allakos Inc. for a project entitled "A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis." Total funding will be $326,771.

David Leiman of Gastroenterology has received an award from Allakos Inc. for a project entitled "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Who Have an Inadequate R." Total funding will be $253,815.

Harry Erba of Hematologic Malignancies and Cellular Therapy has received an award from Jazz Pharmaceuticals for a project entitled "Jazz 1b CPX-351 previously untreated AML." Total funding will be $174,717.

Soheir Adam of Hematology has received an award from Novartis Pharmaceuticals Corporation for a project entitled "Phase II study of SEG101 in sickle cell disease patients with Prisprism (SPARTAN)." Total funding will be $180,245.

John Strouse of Hematology has received an award from Baxalta, Inc. for a project entitled "Shire SC Study (A Phase 1/2 randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis.)." Total funding will be $25,369.

Mehri McKellar of Infectious Diseases has received an award from Genentech, Inc. for a project entitled "Randomized study to evaluate Tocilizumab in patients with severe COVID-19 pneumonia (WA42380)." Total funding will be $375,322.

Cameron Wolfe of Infectious Diseases has received an award from Gilead Sciences, Inc. for a project entitled "Phase III, Remdesivir (GS-5734) in severe COVID-19 participants." Total funding will be $326,007.

Cameron Wolfe of Infectious Diseases has received an award from Gilead Sciences, Inc. for a project entitled "Phase III study of Remdesivir in Moderate COVID-19 patients." Total funding will be $326,007.

Andrew Armstrong of Medical Oncology has received an award from Merck Sharp & Dohme for a project entitled "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)." Total funding will be $1,968,319.

Jennifer Choe of Medical Oncology has received an award from Merck Sharp & Dohme for a project entitled "LEAP-MK-7902-010." Total funding will be $1,507,790.

Jeffrey Clarke of Medical Oncology has received an award from Grid Therapeutics LLC for a project entitled "Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)." Total funding will be $1,457,274.

Daniel George of Medical Oncology has received an award from Modra Pharmaceuticals for a project entitled "A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane." Total funding will be $5,000.

John Strickler of Medical Oncology has received a sub-award () through Bayer HealthCare AG for a project entitled "A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)." Total funding will be $102,109.